注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Eledon Pharmaceuticals Inc是一家临床阶段的生物制药公司。该公司专注于为需要器官或细胞移植、患有自身免疫性疾病及患有肌萎缩侧索硬化症(ALS)的人开发靶向药物。该公司开发中的先导化合物是AT-1501,一种IgG1抗CD40L抗体,对CD40配体(CD40L,也称为CD154)具有高亲和力。与其他抗CD40方法相比,AT-1501旨在提高安全性并提供药代动力学、药效学和剂量优势,阻断CD40L可抑制CD40和CD11共刺激信号通路,具有更好疗效的潜力。该公司从事开发多达四种适应症的AT-1501,包括:ALS、肾脏同种异体移植排斥预防产品、胰岛细胞同种异体移植排斥预防产品和IgA肾病(IgAN产品)。该公司已经在志愿者和肌萎缩侧索硬化症(ALS)患者中完成了Ia/Ib期单次递增剂量试验。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Keith A. Katkin | 53 | 2017 | Independent Chairman of the Board |
David-Alexandre C. Gros | 52 | 2020 | CEO & Non Independent Director |
Hamid Djalilian | - | 2018 | Member of Scientific Advisory Board |
Tal Marom | - | 2018 | Member of Scientific Advisory Board |
Seth Pranksy | - | 2018 | Member of Scientific Advisory Board |
John S. McBride | 72 | 2017 | Independent Director |
Michael E. Pichichero | - | 2018 | Member of Scientific Advisory Board |
Anne GM Schilder | - | 2018 | Member of Scientific Advisory Board |
Paola Marchisio | - | 2018 | Member of Scientific Advisory Board |
Steven N. Perrin | 58 | 2020 | President, Chief Scientific Officer & Non Independent Director |
Walter C. Ogier | 67 | 2020 | Independent Director |
Jan L. Hillson | 71 | 2021 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核